Diprovocim|cas:2170867-89-5|西域试剂

Diprovocim,98.35%

产品编号：Bellancom-123942| CAS NO：2170867-89-5| 分子式：C₅₆H₅₆N₆O₆| 分子量：909.08

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-123942	￥1600.00	杭州北京（现货）
Bellancom-123942	￥2800.00	杭州北京（现货）
Bellancom-123942	￥6100.00	杭州北京（现货）
Bellancom-123942	￥10500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Diprovocim

产品介绍

Diprovocim 是一种有效的 TLR1/TLR2 激动剂。Diprovocim 在人 THP-1 细胞中引发完全激动剂活性 (EC₅₀=110 pM)。Diprovocim 刺激小鼠巨噬细胞释放 TNF-α (EC₅₀=1.3 nM)。Diprovocim 激活下游 MAPK 和 NF-κB 信号通路。Diprovocim 在小鼠中显示出很强的佐剂活性，尤其是促进细胞免疫反应。

生物活性

Diprovocim is a potent TLR1/TLR2 agonist. Diprovocim elicits full agonist activity in human THP-1 cells (EC₅₀=110 pM). Diprovocim stimulates the release of TNF-α from mouse macrophages (EC₅₀=1.3 nM). Diprovocim activates downstream MAPK and NF-κB signaling pathway. Diprovocim displays strong adjuvant activity in mice, particularly abetting cellular immune responses.

体外研究

Diprovocim (在 THP-1 细胞中为 5 nM, 在小鼠腹膜巨噬细胞中为 500 nM; 15-120 分钟) 诱导 IKKα、IKKβ、p38、JNK 和 ERK 的磷酸化，以及 IκBα 的降解。
Diprovocim (0.01-10000 nM; 4 小时) 诱导 THP-1 细胞 (EC₅₀=110 pM)、人外周血单核细胞 (PBMC) (EC₅₀=875 pM) 和小鼠腹腔巨噬细胞 (EC₅₀=1.3 nM) 和骨髓来源的树突状细胞 (BMDC) (EC₅₀=6.7 nM) 产生剂量依赖性 TNF。除 TNF 外，Diprovocim 还诱导小鼠 BMDC 产生 IL-6。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	THP-1 cells and mouse peritoneal macrophages
Concentration:	5 nM in THP-1 and 500 nM in mouse peritoneal macrophages
Incubation Time:	15, 30, 60, 120 mins
Result:	Induced phosphorylation of IKKα, IKKβ, p38, JNK, and ERK, as well as degradation of IκBα.

体内研究
(In Vivo)

Diprovocim (10 mg/kg) 用作佐剂，在与卵清蛋白 (OVA; 100 μg) 混合并肌肉注射，14 天后检测发现可以诱导相似水平的血清 OVA 特异性 IgG。
Diprovocim (10 mg/kg) 与卵清蛋白 (OVA; 100 μg) 混合后，在接种 B16-OVA 细胞免疫前进行肌肉注射，可以显着减缓肿瘤生长速度。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	WT or Tlr2^−/− C57BL/6J mice
Dosage:	10 mg/kg
Administration:	IM
Result:	Induced similar levels of serum OVA-specific IgG, which were highly elevated compared with levels induced by immunization with OVA plus vehicle by i.m. with 100 μg OVA mixed with this drug.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	WT or Tlr2^−/− C57BL/6J mice
Dosage:	10 mg/kg
Administration:	IM
Result:	Induced similar levels of serum OVA-specific IgG, which were highly elevated compared with levels induced by immunization with OVA plus vehicle by i.m. with 100 μg OVA mixed with this drug.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	WT or Tlr2^−/− C57BL/6J mice
Dosage:	10 mg/kg
Administration:	IM
Result:	Induced similar levels of serum OVA-specific IgG, which were highly elevated compared with levels induced by immunization with OVA plus vehicle by i.m. with 100 μg OVA mixed with this drug.

性状

Solid

溶解性数据

In Vitro:

DMSO : 33.33 mg/mL (36.66 mM; ultrasonic and warming and heat to 60°C)

H₂O : < 0.1 mg/mL (ultrasonic) (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.1000 mL	5.5001 mL	11.0001 mL
5 mM	0.2200 mL	1.1000 mL	2.2000 mL
10 mM	0.1100 mL	0.5500 mL	1.1000 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: 2.5 mg/mL (2.75 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (2.75 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。